NCT00087685View on ClinicalTrials.gov

RAD001 in Recurrent Endometrial Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Endometrial Cancer
Interventions
DRUG

RAD001

10 mg by mouth Daily

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00087685 - RAD001 in Recurrent Endometrial Cancer Patients | Biotech Hunter | Biotech Hunter